420 with CNW — How No-Till Cultivation Can Be Beneficial to Marijuana Growers

There is an emerging trend in which marijuana growers are switching to techniques that involve the use of living soil, such as the no-till method, to grow their crops. This method is increasing in popularity because of its beneficial effects on the environment, its ability to reduce grower costs and its positive effects on the quality of the marijuana harvested at the end of the grow cycle.

In this system, the soil isn’t cultivated as is usually the case in conventional agriculture. Instead, mulch and cover crops are used to provide an enabling environment for the robust proliferation of microorganisms, which break down nutrients and make them available to the marijuana plants. For example, networks of fungus can break down minerals contained in the rocks within the soil so that marijuana roots can absorb them for use by a grower’s plants.

By doing away with topsoil tilling, cannabis growers eliminate the need to purchase costly cultivation equipment and instead rely on simple hand tools. Additionally, there is hardly a need to apply synthetic fertilizers, especially after a few years when the soil is now healthy and can avail all the nutrients marijuana plants need on a continuous basis.

Talk about the commercial cultivation of marijuana and many people will immediately think about how much water the system guzzles on a daily basis. With no-till cultivation, water use is minimized since the living soil with its plentiful organic matter retains water more effectively than soil that is cultivated in the conventional way. The mulch covering the soil prevents evaporation since the soil is shielded from the harsh rays of the sun.

Josh Turner, Massachusetts-based Green Meadow’s VP in charge of cultivation, says that no-till systems yield marijuana with a higher potency and a richer terpene profile. This makes sense given that the microorganisms in the soil make various nutrients from rocks, plant debris and soil available to marijuana plants, thereby enabling the cannabis to be of a high quality.

However, cannabis growers planning to switch to the no-till system need to be patient because it takes several years for living soil to establish itself. Additionally, the initial stages of this method are costly. However, once the living soil reaches a point when it is self-sustaining, those initial costs can be recovered over the subsequent years when input is minimal.

An inevitable consequence of creating a rich living soil is that weeds will compete with marijuana plants due to the presence of rich nutrients in the soil. To manage these weeds, mulch the cultivation beds and rotate the cover crops so that weed development is stifled.

As inflation soars and the population becomes more picky about where they spend their money, cannabis sector players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are having to get very creative so that their products remain competitively priced in order to maintain or even grow their market share in the jurisdictions where they operate. No-till farming is one of the cost-cutting options on the table.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed in vitro preclinical testing and in vivo animal and human clinical studies…. Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. [In March], Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity, the first in a series of additional planned animal studies tentatively set to commence this year,” a recent article reads. “‘DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,’ Lexaria CEO Chris Bunka wrote in a recent letter to shareholders.”

To view the full article, visit https://cnw.fm/dHpXY

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Patent Portfolio with Novel Cannabinoid Analogs, Initiates Strategic Research Collaboration Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the publication of a patent application in North America. The application has broad claims directed to the molecular structure, uses and methods of manufacturing of several cannabinoid analogs. Describing several new cannabinoid-related chemical compounds, the broad patent application, if granted, allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (“NCEs”). “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs,” said Eric Hsu, SVP, pre-clinical research and development for InMed. “This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.”

The company has initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone. An international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance, Dr. Maccarrone is the 2007 recipient of the International Association for Cannabinoid Medicines’ prestigious Ester Fride Award for Basic Research. He is also the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award. Dr. Maccarrone’s lab will be screening InMed’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.

To view the full press release, visit https://cnw.fm/kTuGS

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Achieves Integration Milestone with First-Ever Sourcing of Its CBD into Market-Ready Products

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of cannabis products and brands, today announced that it has formally begun the integration of its licensed and Control Union Medical Cannabis Standard GACP (“CUMCS-GACP”) certified cannabis products and derivatives into its global roster of branded products. Beginning with CBD derivatives used in Mind Naturals, its award-winning skincare brand, the company has begun the process of integrating significantly lower-cost cannabinoids, grown and extracted at Flora’s cultivation and extraction facility, Cosechemos, for products formulated at the company’s GMP-licensed laboratory in Bogota, Colombia. The move marks a milestone in the company’s integration strategy, allowing Flora to further its global supply chain efficiencies and independence while bolstering its competitive advantage in white label and wholesale businesses. “The key to unlocking the potential of the global cannabis market is supply chain mastery — this is our focus,” said Flora CEO Luis Merchan. “Connecting our high-quality derivatives with our significant portfolio of revenue-producing global brands is a significant step in maximizing compounded value creation from seed to shelf.”

To view the full press release, visit https://cnw.fm/Ddvpy

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Poll Says Most Americans Want Cannabis Federally Legalized

America has prohibited cannabis at the federal level for decades, prosecuting and sentencing people with cannabis-related convictions harshly. Even though dozens of states have now legalized cannabis and several lawmakers are working on federal legalization bills, it is unlikely that marijuana will be federally legalized any time soon.

However, drug-reform activists and industry stakeholders will be glad to know that a significant percentage of the American population supports federal legalization. A recent poll by CBS News revealed that two-thirds of U.S. citizens would like cannabis to be legal at both the state and federal levels.

Additionally, most people said that they wouldn’t mind having a licensed cannabis business in their community. At the moment, 18 states have legalized recreational cannabis while 37 states allow medical marijuana.

The House has passed a bill that would federally legalize cannabis and launch a legal market several times, but the bill has repeatedly failed to advance past the Senate. Senate Majority Leader Chuck Schumer is also planning on formally unveiling a cannabis legalization bill before the August recess, but it is unlikely to advance past the Senate without the support of GOP senators.

One reason for the public’s general support for marijuana legalization could be financial interest. The cannabis market is insanely lucrative, generating billions of dollars in sales and filling up state coffers with millions in tax revenue.

A significant portion of the taxes derived from cannabis sales has been invested in community programs that help the disadvantaged as well as communities that were disproportionately affected by the drug war. The cannabis industry is also a major job creator and has employed more than 300,000 people.

According to the CBS News poll, three in ten (30%) Americans opposed the idea of having a legal recreational cannabis business in their neighborhoods. Expectedly, most of these folks were also opposed to the idea of legalizing recreational cannabis in the first place. In addition, 36% of those who were polled said they didn’t care either way. Most of those who revealed that they use cannabis (37% of Americans) were even more supportive of legalizing the plant and didn’t mind having a cannabis business in their neighborhoods.

Only a small portion of those who said they don’t use cannabis supported legalization. Unsurprisingly, they didn’t support cannabis reform as strongly as those who said they use cannabis and were not as enthusiastic about a cannabis business pitching a tent in their communities.

Even so, most of them were generally in favor of cannabis legalization or said they didn’t care much about the issue. Such opinions in favor of legalization raise the hopes of the entire cannabis industry, including companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), that public pressure could gradually mount and force the federal government to act on this issue.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Top Democrat in Florida Sues Federal Government Over Gun Rights of Marijuana Users

Cannabis users in America often run afoul of federal law for consuming state-legal cannabis. Since federal law still classifies cannabis as a Schedule I controlled substance with no accepted medical applications and a high risk of abuse, federal institutions strictly prohibit it.

The result is cannabis users being penalized for engaging in actions that are legal in their home states. This includes a federal rule that prohibits marijuana users from purchasing a gun. Gun buyers have to fill out a federal form that includes a question on whether or not they use cannabis.

The form explicitly states that cannabis is illegal under federal law. Individuals who use state-legal marijuana are required to check yes, which results in their purchase being denied. If a marijuana user checks no, they could be subject to up to five years of imprisonment for lying about their marijuana use.

A recent NBC News report reveals that a top Florida Democrat is out to change this. Agriculture Commissioner Nikkie Fried, the sole elected Democrat in Florida, is planning on suing the Biden administration in a bid to block the federal law that prohibits cannabis users from purchasing firearms.

The lawsuit argues that the federal law is in violation of the Second Amendment rights of medical marijuana patients as well as a congressional budget prohibition that bars federal agents from impinging on state cannabis laws.

According to NBC News, Fried intended to file the lawsuit on April 20. If it is successful, it won’t just affect medical cannabis users in Florida; 37 states now have legal medical marijuana markets while 18 states allow the sale of recreational marijuana.

Fries’s office states that there are 2.5 million Floridians with concealed carry permits. Furthermore, a whopping 71% of voters in the state voted to legalize medical cannabis in 2016, and a recent survey found that 76% of the Floridians also support legalizing adult-use cannabis.

This majority support for cannabis reform is what allowed Fried, who ran on a promarijuana platform, to clinch her seat. She is bringing the lawsuit with three Florida citizens who have been affected by the federal rule in her official capacity as the Agriculture Commissioner.

Both guns and marijuana are legal in Florida, Fried says, and this lawsuit is about defending people’s rights to access both. While it is risky for her to sue the Biden administration in an election year, she states that her office has received numerous complaints.

Attorney General Merrick Garland and Marvin G. Richardson, acting director of the Bureau of Alcohol, Tobacco, Firearms, and Explosives have been named in the suit as defendants.

The proceedings of this case are likely to be followed closely by marijuana industry actors such as American Cannabis Partners, whose clients remain unsure of whether their gun rights will be taken away once they consume marijuana.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

O’Cannabiz Conference Expo & Awards to Boost Local Cannabis Trade and Networking

Explore the world of cannabis and navigate the immense networking opportunities offered at the O’Cannabiz Conference Expo & Awards from June 1-3, 2022. This event offers a phenomenal stage for traders, cultivators, marketers, regulators, researchers, and cannabis businesses in the region to get recognition on the global forum, amongst the stalwarts of the cannabis space.

This year, the conference is being organized by O’Cannabiz Conference Expo & Awards as a physical event at the International Centre- Hall#5, Ontario, Canada, after being canceled last year due to COVID-19. The Conference and Expo will be held at the 50,000 sq. ft hall with 3500+ attendees networking in 70+ interactive sessions, with 180+ industry leaders speaking about cannabis trading, laws and regulations, the scope and future of industries, as well as the compliance in Canada.

The participants will be welcomed by a Red Carpet Royalty Cocktail Reception, followed by a dinner and awards ceremony, and an after-party session with VIP networking for exhibitors, sponsors, and delegates. The event group is a pioneer in hosting high-tech events to open networking avenues among traders, businesses, enthusiasts, and government bodies across the entire spectrum of industries. The event will also showcase O’Cannabiz Industry Gala Awards, hosted by Gerry Dee, where the team will honor Tommy Chong with a Lifetime Achievement Award along w ith his celebrity interview.

The next day is followed by exhibits and respective booths where cannabis industries and retailers can showcase their business ideas and get discovered by potential investors. Seek in-depth knowledge and insights from the spectacular line-up of speakers and become a part of engaging sessions where these influencers will discuss a plethora of topics across the entire spectrum of cannabis industries and trade.

At the O’Cannabiz Conference Expo & Awards, the teams take up the initiative of connecting investors, traders, retailers, exhibitors, and regulators of cannabis use and trade over a common stage. They have organized global trade summit initiatives and are experienced to handle government entities and have worked with the Canadian government.

The Conference will include sessions on the Psychedelic trade, its regulations, laws, and viability from a commercial standpoint. Attendees will also get an opportunity o to connect with investors, peers, and influencers during the networking breaks. They can leverage this opportunity to connect ad develop long-term ties with business associates and discover new prospects.

To know more, please visit https://ocannabiz.com/.

About CannabisNewsWire

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lift&Co. Expo Toronto 2022 – Lift Cannabis Business Conference To Offer Important Learning and Networking Sessions

Become a part of Canada’s #1 Cannabis Conference and Trade Show for a full-day immersive learning experience about Cannabis business and trade at the Lift Cannabis Business Conference on May 12, 2022. The business conference is a part of the 4-day Lift&Co. Expo Toronto 2022 that is being held at the Metro Toronto Convention Centre.

The Cannabis Business Conference will be attended by cannabis business leaders from across North America and around the world and will feature speaker sessions and presentations to impart the latest intelligence on myriad aspects of the cannabis industry. Connect with the experts, innovators, regulators, and leaders of the cannabis business community, build long-term business ties, and get discovered by potential investors within this robust networking forum.

The Lift Cannabis Business Conference commences at 9:00 am with opening remarks from Dr. Sherry Boodram, CEO & Co-Founder, CannDelta.

Below is an at-a-glance agenda for the conference:

World In Review: The rapidly-growing Canadian and global cannabis markets-opportunities, statistics and latest trends for 2022-2023.
Next-Gen Spotlights: Discussion on two important product innovations in cannabis.

The Future is Coming Fast for Rapid Delivery Cannabis-How rapid delivery works, potential applications for patients and consumers, and what are the current roadblocks, business potential, and future.
The Progress Toward Odorless Cannabis-Research and results, future potential, consumer trends, and more.

CSR Shift: Evolution of the cannabis business and its social impact-collaborations with non-profits, challenges with the current regulations, promoting responsible use, and promoting the safe and responsible use of cannabis.
Economic Shift: Establishing an Industry panel for Innovation, Science, and Economic Development that includes members of the industry, regulators, and policymakers, who discuss and monitor the industry’s economic development needs and tackle challenges within the sector.
Production and Profitability: Streamlining supply, demand, and business growth in a rapidly evolving market.
Risk and Profitability: How current and emerging trends impact risk management and profitability.
The Next Big New Product Category: Which new wellness products will hit the market?
Craft and Premium: Best micro-producers and top shelf brands.
Canada’s Cannabis Legislation Review: What to expect following the review.
Competitive Strategy: Insights on winning competitive strategies in the cannabis sector.

The Lift Cannabis Business Conference represents an unmatched learning experience for both established and new businesses in the cannabis industry. Tickets for the conference also include lunch, a private reception on the evening of May 12, and access to all three days of the Lift&Co. Expo Exhibit Hall, May 13-15, 2022.

To learn more, please visit https://liftexpo.ca.

About CannabisNewsWire

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data

Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs
Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment (https://cnw.fm/jDeE3).

During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the National Center for Health Statistics of the Centers for Disease Control and Prevention at selected times, while 24 percent of the individuals took three or more prescriptions and 13 percent took five or more (https://cnw.fm/dQJac).

The data showed a marked increase over those persons sampled during the late 1980s to mid-1990s, particularly where multiple medications were concerned. And yet, a recent news report states that as few as 50 percent of patients take their medications exactly as prescribed (https://cnw.fm/pjMQN).

Global drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in their approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many of the obstacles that may hinder their proper use by patients.

The company’s patented DehydraTECH(TM) technology combines an active pharmaceutical ingredient (“API”) with a fatty acid oil and performing a patented dehydration synthesis process before ingestion The Company has demonstrated significant improvements of absorption into bloodstream and even into brain tissue, in as little as minutes after ingestion.

One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (“CBD”) for the treatment of hypertension under the Investigational New Drug (“IND”) process.

Lexaria recently announced the launch of its HYPER-H21-4 randomized, double blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness (https://cnw.fm/Wg5qZ).

Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 (https://cnw.fm/qGvMi) and HYPER-H21-2 (https://cnw.fm/Na1s4) provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings (https://cnw.fm/nFuNt).

HYPER-H21-3 used a placebo-controlled and double-blinded design with 16 volunteers, safely simulating hypoxia conditions (reduced oxygen availability) to induce lung artery constriction, or pulmonary hypertension, to analyze the ability of DehydraTECH-CBD to reduce pulmonary artery systolic pressure.

HYPER-H21-4 will include 60 people and will be the most comprehensive study Lexaria has conducted to date. Dosing in more than half the volunteers has already begun and all treatment visits are expected to be finished by early July.

The volunteers are between the ages of 40 and 70 with documented or measured elevated blood pressure, mild hypertension or moderate (stage 2) hypertension. The participants will use an escalating dose of DehydraTECH-CBD every day for a 5-week duration, establishing data for DehydraTECH-CBD’s extended use over time and providing secondary data outcomes that may ultimately lead to additional applications for DehydraTECH-CBD, according to the company.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “CCWIRE” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

420 with CNW — New Poll Suggests Parents Are Willing to Give Kids CBD

Cannabidiol (CBD) is a chemical compound produced by plants in the cannabis family. Since most of the CBD on the American market is extracted from hemp, a nonpsychoactive form of cannabis, cannabidiol will not intoxicate you. For the past couple of years, people have been turning to this hemp extract as an alternative medicine for a variety of health problems. Studies have shown that it can be effective at alleviating the symptoms of medical conditions such as chronic pain, anxiety depression and insomnia.

Furthermore, the FDA has approved a CBD-based drug called Epidiolex to treat two rare forms of pediatric epilepsy: Dravet syndrome and Lennox-Gastaut syndrome.

Experts have cautioned the public against seeing CBD as a miracle cure that can treat any condition, stating the hype around CBD treatments seems to have eclipsed the science. There is limited research on cannabidiol, and we still don’t know much about its potential benefits and risks, especially over the long term.

This problem becomes even more serious when you consider the fact that there are companies making CBD products for children with barely any regulation from the federal government. And according to a new report from the University of Michigan’s C.S. Mott Children’s Hospital, some parents are willing to give their children CBD.

Researchers surveyed 2,020 parents with at least one child aged one to eighteen years old. They discovered that three in four parents were receptive to the idea of giving their children CBD if other medications were not effective. Sarah Clark, the poll’s codirector, says the results point to parents being more open-minded about CBD treatments.

However, the report noted that most parents do not have access to crucial information about CBD. One-third of the respondents didn’t know that CBD was nonpsychoactive and believed that using the cannabinoid is no different from using marijuana. Such parents would be more likely to prevent their children from using CBD even when they could benefit

Clark believes that parents who don’t understand the difference between CBD and THC (the main psychoactive agent in cannabis) can be properly educated via continued exposure and explanation. On the other hand, she is optimistic that the respondents who expressed that they would give their children CBD if other medications did not work at least have a basic understanding of the cannabinoid. Those parents realize that there is no miracle medicine that can cure every childhood ailment, she says.

The poll also revealed that 83% of parents believed the FDA should regulate CBD products meant for children, and 74% feel that you should have a doctor’s prescription before you can give CBD to your children.

With such a willingness to give CBD to kids, parents could soon take to the cutting-edge cannabis cultivation “micro-farms” made and marketed by entities such as Advanced Container Technologies Inc. (OTC: ACTX) as these companies seek to take matters into their own hands while federal regulators consider ways to regulate this nonintoxicating cannabinoid.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.